Keryx Biopharmaceuticals, Inc. (KERX) ended last trading session with a change of 14.64 percent. It trades at an average volume of 1.57M shares versus 3.8M shares recorded at the end of last trading session. The share price of $5.48 is at a distance of 76.21 percent from its 52-week low and down -29.74 percent versus its peak. The company has a market cap of $580.66M and currently has 105.96M shares outstanding. The share price is currently -1.81 percent versus its SMA20, -5.05 percent versus its SMA50, and -0.92 percent versus its SMA200. The stock has a weekly performance of 15.86 percent and is -6.48 percent year-to-date as of the recent close.
Nov. 18, 2016 — Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, announced case study data, which showed that Auryxia® (ferric citrate) lowered and maintained serum phosphorus levels in chronic kidney disease (CKD) patients on dialysis. These data were presented in a poster presentation at the American Society of Nephrology’s 2016 Kidney Week taking place in Chicago.
Novavax, Inc. (NVAX) recently recorded -1.54 percent change and currently at $1.28 is 10.34 percent away from its 52-week low and down -84.92 percent versus its peak. It has a past 5-day performance of -3.03 percent and trades at an average volume of 7.54M shares. The stock has a 1-month performance of 0.79 percent and is 1.59 percent year-to-date as of the recent close. There were about 271.28M shares outstanding which made its market cap $347.24M. The share price is currently -5.85 percent versus its SMA20, -4.36 percent versus its SMA50, and -69.32 percent versus its SMA200.
On Jan. 19, 2017 Novavax, Inc. (NVAX) announced the initiation of a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults (60 years of age and older).
The objective of the trial is to assess safety and immunogenicity to one and two dose regimens of the RSV F Vaccine, with and without aluminum phosphate or Novavax` proprietary Matrix-M(TM) adjuvant, in older adults. The trial is a randomized, observer-blinded, placebo-controlled trial designed to enroll up to 300 older adults in the Southern Hemisphere. Participants are being enrolled and vaccinated outside of the RSV season to best assess immunogenicity. Top-line results are expected in the third quarter of 2017.